Development, potency and efficacy test of an inactivated vaccine using the vaccinia virus strain GP2

• Autor(a) principal: Ana Carolina Diniz Matos
• Data de Publicação: 2016
• Tipo de documento: Tese
• Idioma: eng
• Título da fonte: Repositório Institucional da UFMG
• Texto Completo: http://hdl.handle.net/1843/33375
• topic: Bovine vaccinia; Immune response; Vaccine; Vaccinia virus

Bovine vaccinia (BV), caused by Vaccinia virus (VACV), is a zoonosis characterized by exanthematic lesions in the teats of dairy cows and milkers hands. Due to the occurrence of many BV outbreaks in dairy farms in all Brazilian regions, since 1999, there is a need to improve the control and prevention measures of the disease. Vaccination is one of the major tools to prevent viral diseases, and it could be an alternative for BV prevention. The main objective of the research was the development of vaccine formulations against BV using the inactivated VACV strain GP2 as antigen combined with different adjuvants. Then, potency and efficacy tests were performed in mice and cattle. VACV strain GP2, inactivated by BPL in association with adjuvants was effective to induce a humoral immune response against infection by the homologous VACV in Balb/c murine model. The induction of the humoral immune response, as measured by neutralizing antibody (NA) titration was variable according to the adjuvant used with the viral antigen. The vaccine formulation using aluminum hydroxide associated with saponin as adjuvants induced high titers of NA in all vaccinated mice, giving 100% protection in Balb/c murine model after the challenge. This formulation was selected and tested in cattle. In the target species, bovine, this vaccine formulation was able to induce the production of NA and activate cellular immune responses after challenge, conferring 100% protection against clinical signs in vaccinated heifers submitted to the challenge by VACV-GP2